Home  |  Contact

Cellosaurus P3X63Ag8 (CVCL_3411)

[Text version]
Cell line name P3X63Ag8
Synonyms P3x63Ag8; P3-X63-Ag8; P3/X63-Ag8; P3/X63 Ag8; P3/X63/Ag8; P3X63Ag.8; P3-X63Ag8; P3X63 Ag8; P3x63 Ag8; P3 x 63Ag8; P3 X 63 Ag8; X63-Ag8; X63-AG8; x63-Ag8; P3X63; X-63; X63; GM03571
Accession CVCL_3411
Resource Identification Initiative To cite this cell line use: P3X63Ag8 (RRID:CVCL_3411)
Comments Group: Hybridoma fusion partner cell line.
Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981).
Doubling time: 16-26 hours (ECACC=85011401).
Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine.
Misspelling: P3-X67Ag8; PubMed=1172191; Note=In figures and table 1.
Disease Mouse plasma cell myeloma (NCIt: C125417)
Species of origin Mus musculus (Mouse) (NCBI Taxonomy: 10090)
Breed/subspecies: BALB/c.
Hierarchy Parent: CVCL_T278 (P3K)
Children:
CVCL_B0T4 (1083-17-1A) CVCL_C4PR (10B/2C) CVCL_A6LE (11/9)
CVCL_B0T5 (1116-56-2) CVCL_G218 (1116NS-19-9) CVCL_7233 (1116NS-3d)
CVCL_J039 (129A3/1) CVCL_J042 (130-3-F7-5) CVCL_J040 (130C3/2B/8)
CVCL_J041 (132C4A/4) CVCL_J043 (143-2-A6-11) CVCL_J081 (151-5-G2-12)
CVCL_J082 (151-5-G3-5) CVCL_J083 (151-6-A7-9) CVCL_J084 (15F3-1)
CVCL_A0AE (168A51-2) CVCL_A0AF (168A51-42) CVCL_A0AA (168B17-46-34)
CVCL_A0AB (168B17-46-50) CVCL_A0AC (168B17-46-70) CVCL_A0AD (168B17-46-92)
CVCL_WS75 (18B8) CVCL_J099 (1A3 [Mouse hybridoma against HeLa]) CVCL_B0VL (1C1 [Mouse hybridoma against FeLV gp70])
CVCL_B0WJ (1C11 [Mouse hybridoma against FIV p24]) CVCL_B0VM (1C12 [Mouse hybridoma against FeLV p15E]) CVCL_J164 (1G12)
CVCL_B7G9 (1G7 [Mouse hybridoma against I.punctatus Ig light chains]) CVCL_J165 (1H10-6) CVCL_J511 (200-3-G6-4)
CVCL_CW45 (227-341-4) CVCL_J628 (2C5-6) CVCL_C4PS (2D/11C)
CVCL_C4PT (2F/11F) CVCL_J720 (3-83P) CVCL_B0WK (3B7 [Mouse hybridoma against FIV p24])
CVCL_KB11 (3C5 [Mouse hybridoma against A.australis AaH2]) CVCL_B7GA (3F12 [Mouse hybridoma against I.punctatus Ig light chains]) CVCL_D292 (3H5-1)
CVCL_C7XD (4A7) CVCL_B0VN (4B1) CVCL_KB12 (4C1 [Mouse hybridoma against A.australis AaH2])
CVCL_J813 (4D12 [Mouse hybridoma against human B2M/HLA-B]) CVCL_G092 (4F2C13) CVCL_J887 (4SB3)
CVCL_J928 (5D4-11) CVCL_B6Q9 (691-13) CVCL_B6QB (691-19)
CVCL_B6QD (691-2) CVCL_B6QF (691-4) CVCL_B6QJ (691-6)
CVCL_B6Q7 (691-I-5Nu 4) CVCL_B0VP (6B2 [Mouse hybridoma against FeLV p15E]) CVCL_B0VQ (6D4)
CVCL_B0VR (6G3) CVCL_B0VS (7B3) CVCL_C4PW (7F1/6B)
CVCL_J052 (7R2/A4) CVCL_KS90 (8-18C5) CVCL_B0VT (8F3)
CVCL_KB13 (9C2) CVCL_B0WP (A1.1) CVCL_XK76 (A17.2#1)
CVCL_J974 (A1G3) CVCL_XK77 (A25.1#1B3) CVCL_7946 (A2B5 clone 105)
CVCL_A7QK (A3D8) CVCL_L673 (Antibody 2.06) CVCL_XH98 (AS 2)
CVCL_XH99 (AS 3) CVCL_J158 (Aw3.18.14) CVCL_J977 (B1 NIH)
CVCL_C4BP (B1-46) CVCL_C4BQ (B1-48) CVCL_C4BR (B1-52)
CVCL_C4BN (B1-8) CVCL_B0WQ (B1.1) CVCL_A2DD (B1.12)
CVCL_XK78 (B16.1#1B2) CVCL_XK79 (B16.1#1B6) CVCL_XK80 (B16.1#1C1)
CVCL_XK81 (B16.1#1C5) CVCL_XK82 (B16.1#2A2) CVCL_XK83 (B16.1#2A3)
CVCL_XK84 (B16.1#2A5) CVCL_XK85 (B16.1#2C4) CVCL_XK86 (B16.1#2D2)
CVCL_XK87 (B16.1#2D5) CVCL_L832 (B1D6) CVCL_B0WR (B2.1)
CVCL_A2DE (B2.10) CVCL_A2DF (B2.12) CVCL_J978 (B3 NIH)
CVCL_B0WS (B3.1) CVCL_J979 (B5 NIH) CVCL_C4BT (B53-12)
CVCL_C4BS (B53-8) CVCL_4506 (BBM.1) CVCL_J449 (C11C1)
CVCL_KR90 (C17.9C6) CVCL_B5N0 (CCM-52) CVCL_L835 (CIIC1)
CVCL_C3TV (CIIC2) CVCL_C4SM (Cyd-1) CVCL_J890 (D1-4G2-4-15)
CVCL_J891 (D3-2H2-9-21) CVCL_G367 (D8G) CVCL_A1LH (DU-ALL-1)
CVCL_A6WW (ECCD-1) CVCL_A6WX (ECCD-2) CVCL_J226 (F1-3G8-1)
CVCL_J237 (F11G) CVCL_H150 (GM03566) CVCL_H151 (GM03568)
CVCL_H149 (GM03705) CVCL_JE56 (GM03713) CVCL_H152 (GM04279)
CVCL_H153 (GM04280) CVCL_C4SN (Guo-1) CVCL_C4SP (Guo-2)
CVCL_5J83 (H14-A11) CVCL_KR61 (H14-A2) CVCL_5J84 (H14-A20)
CVCL_5J85 (H14-A21) CVCL_5J86 (H14-B18) CVCL_C5MJ (H16C08)
CVCL_C5MK (H16E07) CVCL_C5KK (H17-L10) CVCL_C5KL (H17-L19)
CVCL_C5KM (H17-L2) CVCL_5K00 (H17-L8) CVCL_C5ML (H17B11)
CVCL_C5MM (H17D09) CVCL_C5MN (H17D12) CVCL_5K02 (H18-S210)
CVCL_C5MP (H19B10) CVCL_C5MQ (H19D03) CVCL_5K06 (H2-4B3)
CVCL_5K07 (H2-4C2) CVCL_5K08 (H2-6A1) CVCL_C5KN (H2-6C4)
CVCL_C5MR (H20C01) CVCL_C5MS (H20E03) CVCL_C5MT (H20F04)
CVCL_C5MU (H21C08) CVCL_C5MV (H22F02) CVCL_C5MW (H22F05)
CVCL_C5MX (H23B05) CVCL_C5MY (H23D02) CVCL_C5MZ (H23F10)
CVCL_C5N0 (H24E07) CVCL_C5N1 (H26A09) CVCL_C5N2 (H26D02)
CVCL_C5N3 (H26D08) CVCL_C5N4 (H26F02) CVCL_C5L6 (H28-A2)
CVCL_C5L7 (H28-D14) CVCL_C5IE (H28-E23) CVCL_C5LA (H3-4C5)
CVCL_B7B9 (H4A3) CVCL_B7BA (H4B4) CVCL_B7BB (H4C4)
CVCL_B7BC (H4F8) CVCL_B7BD (H4H3) CVCL_B7BE (H52)
CVCL_B7BF (H5A4) CVCL_B7BI (H5B9) CVCL_B7BG (H5C6)
CVCL_B7BH (H5D2) CVCL_B7BJ (H5G11) CVCL_L842 (H6/31HL)
CVCL_C5LI (H8-2D1) CVCL_5J96 (H9-A15) CVCL_5J97 (H9-D3)
CVCL_E979 (HFN 36.3) CVCL_E980 (HFN 7.1) CVCL_3441 (HK-PEG-1)
CVCL_2502 (HO-13-4) CVCL_2503 (HO-2.2) CVCL_2504 (HO-22-1)
CVCL_VU59 (Hybrid 15B) CVCL_VU60 (Hybrid 26A7) CVCL_VU61 (Hybrid 27-1)
CVCL_A2IG (I101C9-R1A5) CVCL_A2IH (I101D4-R1D8) CVCL_A2IK (I101F5-R1G2)
CVCL_A2II (I101F8-R1G5) CVCL_A2IJ (I101H12-R1GB) CVCL_DC76 (IgE-14-205)
CVCL_G127 (IL-A11) CVCL_L579 (IL-A12) CVCL_B6SG (IST-1 [Mouse hybridoma against human FN])
CVCL_B6SH (IST-2) CVCL_B6SI (IST-3) CVCL_B6SJ (IST-4)
CVCL_B6SK (IST-9) CVCL_G198 (J5 [Mouse hybridoma]) CVCL_J814 (LS-136)
CVCL_D3F7 (M2D1) CVCL_L582 (Mab 126) CVCL_L583 (mAb 13-1)
CVCL_L584 (mAb 13-2) CVCL_C8BT (Mab 213) CVCL_L588 (mAb 24-1)
CVCL_L589 (mAb 24-2) CVCL_A6QY (MAO A-3C9) CVCL_A6QZ (MAO A-4F10)
CVCL_A6RA (MAO A-7B10) CVCL_A6RB (MAO A-7E10) CVCL_A6QX (MAO B-1C2)
CVCL_A6GC (MAR 103.6) CVCL_D294 (MAR 18.5) CVCL_A6FM (MAR 80.2)
CVCL_B6S1 (ME109) CVCL_B6S2 (ME121) CVCL_B6S3 (ME165)
CVCL_B6S4 (ME325) CVCL_B6S5 (ME416) CVCL_B6S6 (ME425)
CVCL_B6S7 (ME491) CVCL_B6S8 (ME492) CVCL_B6S9 (ME493)
CVCL_B6SA (ME510) CVCL_B6SB (ME515) CVCL_A8Q8 (MSN-1)
CVCL_L534 (MT3/B4) CVCL_L535 (MT4/E4) CVCL_C7XC (N11 [Mouse hybridoma against A.viteae tropomyosin])
CVCL_C1CX (NKI/C-3) CVCL_C7XB (NR1) CVCL_UZ12 (P3-Ag8-gamma1-)
CVCL_2155 (P3/NS1/1-Ag4.1) CVCL_4032 (P3X63Ag8.653) CVCL_3412 (P3X63Ag8U.1)
CVCL_LI05 (PI 125/10) CVCL_G250 (PI 153/3) CVCL_B5N1 (RCM-25)
CVCL_B5N2 (RCM-37) CVCL_LG30 (Rx 54-3) CVCL_B6QL (SK 37-7)
CVCL_A6PE (Sp1/7-2) CVCL_2199 (Sp2/0-Ag14) CVCL_A6PD (Sp2/3-3)
CVCL_D677 (SXC1) CVCL_J096 (SXC2) CVCL_F770 (T3-3A1)
CVCL_G093 (T3-5E9) CVCL_F784 (TE4 [Mouse hybridoma against human thymic antigen]) CVCL_C4R3 (V58A4)
CVCL_A2IA (V81C6-R1B6) CVCL_A2IB (V82A6-R1C4) CVCL_A2IF (V82B1-R2D4)
CVCL_A2IC (V82B2-R1F6) CVCL_A2IE (V82G12-R1G1) CVCL_A2ID (V82G3-R1D6)
CVCL_B0D1 (VIIIC3.78) CVCL_7872 (W6/32) CVCL_F817 (XMMME-001)
CVCL_F818 (XMMME-002) CVCL_2Z37 (Y8-10C2)
Sex of cell Female
Category Cancer cell line
Publications

PubMed=1172191; DOI=10.1038/256495a0
Kohler G.J.F., Milstein C.
Continuous cultures of fused cells secreting antibody of predefined specificity.
Nature 256:495-497(1975)

PubMed=825377; DOI=10.1002/eji.1830060713
Kohler G.J.F., Milstein C.
Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion.
Eur. J. Immunol. 6:511-519(1976)

PubMed=6769123; DOI=10.1073/pnas.77.4.2197
Kohler G.J.F.
Immunoglobulin chain loss in hybridoma lines.
Proc. Natl. Acad. Sci. U.S.A. 77:2197-2199(1980)

PubMed=2108149; DOI=10.1016/S0021-9258(19)39438-4
Lee S.-O., Connolly J.M., Ramirez-Soto D., Poretz R.D.
The polypeptide of immunoglobulin G influences its galactosylation in vivo.
J. Biol. Chem. 265:5833-5839(1990)

CLPUB00447
Mulivor R.A., Suchy S.F.
1992/1993 catalog of cell lines. NIGMS human genetic mutant cell repository. 16th edition. October 1992.
(In) Institute for Medical Research (Camden, N.J.) NIH 92-2011; pp.1-918; National Institutes of Health; Bethesda (1992)
Cross-references
Cell line collections (Providers) ATCC; TIB-9
BCRC; 60340
CLS; 305171
Coriell; GM03571
ECACC; 85011401
ICLC; ATL05001
JCRB; JCRB9105
NCI-DTP; P3X63
Cell line databases/resources CLO; CLO_0008334
CLO; CLO_0017237
CLDB; cl3840
CLDB; cl3841
CLDB; cl7165
CCRID; 3101MOUTCM9
Lonza; 186
Anatomy/cell type resources BTO; BTO:0001118
Encyclopedic resources Wikidata; Q54937286
Entry history
Entry creation 04-Apr-2012
Last entry update 29-Jun-2023
Version number 31